HOME >> BIOLOGY >> NEWS
A comparative institutional analysis of intellectual property

Biotech innovations pop up every day. From medicines developed by large companies to ingenious solutions worked out by individuals in university labs, new technologies are poised to enter the marketplace. The question is, are patents helping or hurting this process? "Patents are essential to bringing biotechnology innovations from everyone -- not just well-funded corporations -- to the people," says F. Scott Kieff, J.D., associate professor of law at Washington University in St. Louis.

"Without patents, the biotech marketplace in basic science takes on the nature of something like an old boys' club in which personal attributes such as fame, prestige, and even gender and race, govern what exchanges take place; and the addition of patents gives many more people a way to play in that game."

Kieff presented the paper, "On the Comparative Institutional Economics of Intellectual Property in Biotechnology," on Feb. 19 at the annual meeting of the American Association for the Advancement science, held Feb. 16-20 in St. Louis.

According to Kieff, getting inventions put to use as broadly and rapidly as possible requires many individuals to work with each other, and patent law stands as a beacon around which these individuals can coordinate.

"Adding patents to the field of basic bioscience increases the development of products that are ready for the marketplace even in the face of the real transaction costs of negotiation over patents - such as hiring lawyers, striking deals and enforcing them - precisely because those costs are still lower than the similar transaction costs of negotiating over the academic kudos - such as publications, promotions, and grants - that scientists otherwise trade when they don't have patents," he says.

Kieff notes that allowing legislators, agencies, or courts to break patents when deals over those patents somehow cannot be completed despite strong needs by those wanting a license "would inevitably let big p
'"/>

Contact: Jessica Martin
jessica_martin@wustl.edu
314-935-5251
Washington University in St. Louis
19-Feb-2006


Page: 1 2

Related biology news :

1. National Science Foundation provides $14 million to advance research in comparative genomics
2. Landmark comparative genomics study highlights the importance of junk DNA in higher eukaryotes
3. How many comparative genomes are enough?
4. New comparative toxicogenomics database
5. NIH grants $117 million in institutional development awards to underserved states
6. AAAS analysis finds Congress would add billions to FY 2008 R&D investment
7. Genetic analysis finds greater threat in frog-killing fungus
8. Genomic analysis uncovers new targets for HIV vaccine
9. Manchester University helps with pharaoh DNA analysis
10. UN issues analysis of global investors sustainable energy gold rush
11. Interim analysis of anti-cancer vaccine, BiovaxID, to be conducted

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... ... November 13, 2019 , ... NDA ... RAC , a regulatory affairs and program management executive with more than 33 ... industries, has joined the firm as an Expert Consultant. , Robert Peterson ...
(Date:11/12/2019)... Ore. (PRWEB) , ... November 12, 2019 , ... ... launching Cross-Channel Spend Optimizer that improves digital advertising performance up to 25% and ... Digital Advertising, Cross-Channel Spend Optimizer uses advanced multi-touch attribution (MTA) to predict best ...
(Date:11/9/2019)... ... ... SiteSeer Technologies, creator of SiteSeer Professional retail site selection software, is pleased to ... boutique real estate developer of single and multi-tenant buildings on sites ranging from ½ ... of markets. , Geoffrey Kerth, manager of GPK Acquisitions, says that his firm ...
Breaking Biology News(10 mins):
(Date:11/5/2019)... ... November 04, 2019 , ... ... solutions for drugs, biologics, gene therapies, and consumer health products, today announced ... technology enhances Catalent’s proven GPEx expression platform through multiple improvements, including utilization ...
(Date:11/2/2019)... ... 2019 , ... A clinical trial usually involves many different ... principal investigators, supply chain managers, manufacturers, IRT, CRAs and so on. Lack of ... data, potentially leading to patient risk. , By having a single source of ...
(Date:10/30/2019)... ... ... While using cold plasma to kill cancer cells isn’t an entirely novel ... & Technology are exploring new ways to regulate cold plasma technology to target ... technique would prove to be a drug-free, minimally invasive cancer treatment that would affect ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... its Silver sponsorship and cold chain validation workshop at the Biomanufacturing World Summit ... San Diego, California. , The Biomanufacturing World Summit brings together pharmaceutical ...
Breaking Biology Technology:
Cached News: